About Endologix
Endologix is a company based in Irvine (United States) founded in 1992. Endologix has completed 2 acquisitions, including Nellix and PQ Bypass. Endologix offers products and services including DETOUR System, EVAR Portfolio, ALTO, and AFX2. Endologix operates in a competitive market with competitors including Endoron Medical, Trivascular, Altura Medical, Aptus Endosystems and Remon Medical, among others.
- Headquarter Irvine, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Endologix Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Endologix
Endologix offers a comprehensive portfolio of products and services, including DETOUR System, EVAR Portfolio, ALTO, and AFX2.
Treats peripheral artery disease with minimally invasive interventions.
Provides treatments for aortic aneurysms and vascular conditions.
Offers advanced solutions for endovascular aneurysm repair.
Supports endovascular procedures for vascular health.
People of Endologix
Unlock access to complete
Unlock access to complete
Funding Insights of Endologix
Investors in Endologix
Endologix has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Deerfield and EW Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
|
Locked | Locked | Locked |
Investor details for Endologix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Endologix
Endologix has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Nellix and PQ Bypass.
Investment portfolio details for Endologix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Percutaneous approach for femoral artery bypass
|
Locked | Locked | 2011 | Locked | |
|
Medical device catering less invasive treatment of Abdominal Aortic Aneurysms
|
Locked | Locked | 1994 | Locked |
Complete acquisition details for Endologix
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Endologix
Detailed financials for Endologix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Endologix Comparisons
Peer comparison for Endologix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Endologix
Endologix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Endoron Medical, Trivascular, Altura Medical, Aptus Endosystems and Remon Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Endovascular fixation devices for cardiovascular stent grafts are manufactured.
|
|
| Locked | Locked | Locked |
Designs and manufactures for endovascular aortic repair equipment
|
|
| Locked | Locked | Locked |
Endovascular devices for aortic aneurysms are developed.
|
|
| Locked | Locked | Locked |
Endograft anchoring systems for aortic aneurysms are developed.
|
|
| Locked | Locked | Locked |
Miniature implants are developed to monitor intra-aneurysm pressure and hemodynamics.
|
Detailed competitors of Endologix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Endologix
Complete news archive for Endologix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Endologix
Endologix was founded in 1992 and raised its 1st funding round 18 years after it was founded.
Endologix is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Endologix develops and manufactures minimally invasive treatments for aortic disorders. Endologixs flagship product is the Powerlink System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. It acquired Nellix, a developer of medical devices for the minimally invasive treatment of aortic aneurysms.
Endologix's top competitors include Trivascular, Shanghai MicroPort Endovascular MedTech and Jotec.
Endologix offers DETOUR System, EVAR Portfolio, ALTO, and AFX2.
Endologix has 2 investors. Key investors include Deerfield, and EW Healthcare Partners.